EUCTR2013-004637-33-ES进行中（未招募）不适用
Clinical trial phase III, multicenter, randomised, double-blind, double-dummy, parallel treatment design, active-controlled and placebo, to evaluate the analgesic efficacy and safety of ibuprofen arginine/tramadol 400/37,5 mg compared to ibuprofen arginine 400 mg single, tramadol 50 mg single and placebo in patients with moderate to severe pain after dental surgery.
aboratorios Farmalider S.A.0 个研究点开始时间: 2014年4月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able to understand and sign consent informed before participating in
- •the study and willing to comply with all visits and procedures
- •scheduled and collect the information required by the protocol.
- •2. Men and women of both sexes at least 18 years of age.
- •3. For women: postmenopausal women or unable by surgery, not pregnant women of child-bearing age who use acceptable methods of birth control and normal menstrual period 3 months before the clinical study.
- •4. Body weight of more than 50 Kg and less than 110 Kg.
- •5. Programed people to ambulatory surgical dental removal, under local anesthesia, at least 2 impacted third molars which require bone removal. If only 2 third molars are removed these should be ipsilaterals and at least one of them should require bone removal.
- •6. People with moderate to severe pain, reaching at least 45 mm in EVA scale for the first 4 hours after surgery.
- •7. Surgery without complications, surgery time no more than 1 hour and without re-anesthesia.
- •8. Must accept don´t take analgesics, except rescue medication until treatment described in the Protocol, up to 24 hours after first administration of study medication.
- •9. With ordinary or without relevant abnormalities medical records and physical exploration, to the discretion of the investigator.
- •10. People who have not used up analgesics (including those for prescription and non-prescription sale) until 48 hours before the surgery, or 5 days early in the event of consumption of COX-2 inhibitors.
- •11. For women of childbearing, they should have a negative pregnancy test prior to randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 384
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of allergy or hypersensitivity to the study medication, to the rescue medication or to the any other NSAID, to the opiates or to the acetylsalicylic acid.
- •2. History of asthma, bronchospasm, acute rhinitis, nasal polyps, hives or angioneurotic edema.
- •3. History of peptic ulcers, gastrointestinal disorders caused by NSAID, gastrointestinal bleeding or others active bleedings.
- •4. Renal, hepatic and cardiac dysfunction moderate to severe.
- •5. Coagulation disorders.
- •6. Uncontrolled seizure disorders.
- •7. Crohn's disease or ulcerative colitis.
- •8. History of drug addiction and alcohol abuse. According to the study, alcohol abuse is defined in the following manner: average weekly consumption >21 units (men) and >14 units (women), or average daily consumption >3 units (men) and >2 units (women) [1 unit = 125 ml of wine, 200ml of beer, 25ml of liquor]
- •9. According to the investigator, patients who are not suitable candidates to take the study medication and the rescue medication based on their medical history, concomitant medication systemic concurrent diseases described in the corresponding technical sheets (warnings, precautions, contraindications and adverse events) of ibuprofen, tramadol, paracetamol and metamizole ( paracetamol and metamizole are rescue medication).
- •10. Inability to abstain from alcohol, psychotropic drugs and sedative medications or others drugs banned (*) until 48 hours or 5 half-lives (the longest possible) before the start of surgery and until 24 hours after of administration of study medication.
- •(*)different analgesics from study medication, anticoagulants, thrombolytic and antiplatelet agents, corticosteroids, MAO inhibitors, antiepileptic drugs, antipsychotics, SSRIs and tricyclic antidepressants, lithium, methotrexate, sulfonamides.
- •11. Patients using and don´t be able to interrupt other drugs, prescribed or not, that could interfere with the study medication and study procedures, or could endanger the patient´ safety according to related documentation with the medications included in the study and the rescue medication, until 48 hours or 5 half-lives (the longest possible) before the start of surgery and until 24 hours after of administration of study medication.
- •12. Patients who have taken an experimental medication or patients who have used an experimental medical device within 30 days before to selection.
- •13. Pregnant or nursing women.
- •14. History of any liver disease or disorder which, according to investigator, might constitute a risk to the patient or to alter the results of the study (e.g. patients with severe pain of different origins or location at the surgery moment.)
- •15. Patients who cannot meet the requirements of the study or must not take part according to the investigator.
研究者
相似试验
进行中（未招募）
1 期
Oral treatment to evaluate the analgesic efficacy and safety of paracetamol / ibuprofen 500/200 mg compared with 500 mg paracetamol alone, ibuprofen 200 mg alone and placebo in patients with primary dysmenorrheaMODERATE TO SEVERE PAIN FOLLOWING DYSMENORRHOEAEUCTR2015-002446-31-ESABORATORIOS FARMALIDER S.A.
招募中
3 期
SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia2024-513649-35-00Assistance Publique Hopitaux De Paris, Assistance Publique Hopitaux De Paris84
已完成
不适用
A phase III, multicentre randomised clinical trial comparing gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancerAdvanced Pancreatic CancerPancreaticCancerISRCTN11513444Sponsor not defined (UK)508
进行中（未招募）
不适用
Phase III clinical trial multicenter randomized for the evaluation of the safety and efficacy of the combined treatment of intravitreal triamcinolone and photodynamic therapy versus intravitreal Bevacizumab and photodynamic therapy versus intravitreal Bevacizumab for the treatment of neo-vascular maculopathy type retinal angiomatous prolipheration (RAP). - NDChoroideal neo-vascularization type RAP.MedDRA version: 9.1Level: SOCClassification code 10015919EUCTR2008-001468-34-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not beentreated yet.Human Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-000459-28-ITVIIV HEALTHCARE UK LIMITED722